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marked, may regress slowly, may show intermittent
spontaneous or precipitated crisis-like exacerbation,
and may require prolonged ventilation and specific
strategies to maintain a lower PVR. This is not the case
in the majority of patients, in whom, despite demon-
strable pulmonary endothelial dysfunction, its clinical
manifestations are less obvious. Pulmonary endothelial
dysfunction is almost certainly a specific manifestation
of a more generalized inflammatory reaction associated
with the release of cytokines and other inflammatory
mediators after CPB.2 It is unclear whether pulmonary
endothelial dysfunction itself or as a surrogate of this
systemic inflammatory response syndrome may influ-
ence postoperative recovery, however. Furthermore, the
evolution of surgical algorithms to perform corrective
I n children with congenital heart disease, high pul-monary blood flow and pulmonary artery pressure
lead to an increase in pulmonary vascular resistance
(PVR) preoperatively, which is aggravated by the devel-
opment of overt pulmonary endothelial dysfunction
after cardiopulmonary bypass (CPB).1 In some patients
the postoperative increase of PVR may be more
Objective: We sought to define the contemporary clinical effect of increased
pulmonary vascular resistance in infants after congenital heart operations
with cardiopulmonary bypass.
Methods: Fifteen infants (median age, 0.31 years; median weight, 5.1 kg)
underwent cardiac operations involving cardiopulmonary bypass (range, 49-
147 minutes). Pulmonary vascular resistance was measured in the immedi-
ate postoperative period in the intensive care unit by means of the direct Fick
principle, with respiratory mass spectrometry to measure oxygen consump-
tion. The effect of ventilation with an inspired oxygen fraction of 0.65, with
additional infusion of L-arginine, substance P, and inhaled nitric oxide, was
assessed and subsequently correlated with the length of mechanical ventila-
tion from the end of cardiopulmonary bypass to successful extubation.
Results: Overall, pulmonary vascular resistance at baseline (11.7 ± 5.6 
WU · m2) could be reduced to a minimum of 6.1 ± 3.5 WU  · m2. The ven-
tilatory time was 0.86 to 14.9 days (median, 1.75 days) and correlated direct-
ly with the lowest pulmonary vascular resistance value achieved during the
pulmonary vascular resistance study (r2 = 0.64, P < .01). The patient sub-
group with mechanical ventilation of greater than 2 days had significantly
higher pulmonary vascular resistance at all stages of the study protocol, and
in this group there was a correlation of cardiopulmonary bypass time and
ventilatory support time (r2 = 0.48, P < .05).
Conclusion: Increased pulmonary vascular resistance, either directly or as a
surrogate of the systemic inflammatory response after cardiopulmonary
bypass, continues to have a significant effect on postoperative recovery of
infants after cardiac operations. (J Thorac Cardiovasc Surg 2001;121:1033-9)
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procedures at an earlier age and the development of
improved strategies to manage the PVR in the postop-
erative period have led to the suggestion that the effect
of postoperative elevation of PVR has become a rela-
tively unimportant element of contemporary postopera-
tive care. In this study we analyzed the relationship
between pulmonary endothelial dysfunction, PVR, and
clinical outcome in children at risk of pulmonary
hypertension after operations requiring CPB.
Methods
Patients. The study was approved by the Hospital
Research Ethics Committee, and written informed consent
was obtained from the parents of each child. All patients
underwent surgical correction of the cardiac malformation
with the use of low-flow hypothermic CPB and conventional
ultrafiltration. Dexamethasone was added to the priming
solution at the surgeon’s discretion (Table I). Patients at risk
for postoperative pulmonary hypertension were studied
immediately after the heart operation in the intensive care
unit. All patients were sedated, mechanically ventilated, and
paralyzed (with vecuronium, midazolam, and morphine)
throughout the study. They were intubated with a cuffed
endotracheal tube (Mallinckrodt, Inc, St Louis, Mo) to
exclude any respiratory gas leaks. Volume-controlled ventila-
tion was delivered with a Siemens 900 C ventilator (Siemens
AG, Munich, Germany).
The study protocol was instituted 1 to 2 hours after CPB.
This delay allowed for sufficient time for central rewarming,
adjustment of sedation and inotropic agents, and tracheal suc-
tioning after transfer to the pediatric intensive care unit.
Residual lesions, such as intracardiac shunts, or significant
atrioventricular valve dysfunction were excluded by means of
echocardiography. Thereafter, further handling or therapeutic
intervention during the study protocol was minimized. The
cuff of the endotracheal tube was inflated with a pressure
below the systemic diastolic blood pressure for the duration
of the study protocol, during which continuous monitoring of
hemodynamic pressures, surface electrocardiography, pulse
oxymetry, and end-tidal carbon dioxide concentration (see
below) was performed.
Special metabolic and hemodynamic measurements.
Oxygen consumption (in milliliters per kilogram per minute)
was continuously determined by means of respiratory mass
spectrometry with the mixed expirate inert gas dilution
method and our previously described modification for use in
patients requiring assisted ventilation.3,4 Special care was
taken to detect and exclude any air leaks or carbon dioxide
contamination of the monitoring and ventilatory circuits. The
mass spectrometer was calibrated directly before the study
and then every 30 minutes to exclude any measurement drift.
Systemic arterial and pulmonary arterial pressures, as well
as right and left atrial pressures, were measured, and blood
samples were taken from the pulmonary artery and the left
atrium. The partial pressures for oxygen and carbon dioxide
and hemoglobin saturation were measured by using the spec-
tral absorption method (Chiron 270 CO-Oximeter; Chiron
Corporation, Emeryville, Calif), and the arteriovenous oxy-
gen content difference (in milliliters per liter) and cardiac
output (with the Fick principle; oxygen consumption/arterio-
venous oxygen content difference), were calculated. PVR (ie,
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Table I.  Patient data, clinical course, and PVR
Age Weight BSA XCT Temperature 
Patient No. Diagnosis (y) (kg) (m2) (min) (°C)
1 T21, VSD 0.66 5.9 0.30 50 25
2 VSD 0.64 7.5 0.38 41 30
3 VSD 0.42 5.3 0.30 41 28
4 AoPW, VSD 0.23 4.4 0.27 31 30
5 T21, AVSD 0.64 4.6 0.25 81 18
6 VSD 0.26 5.9 0.30 38 25
7 T21, AVSD 0.64 4.8 0.27 35 24
8 T21, AVSD 0.23 4.3 0.25 92 25
9 VSD 0.26 5.1 0.30 42 30
10 T21, VSD, PDA 0.56 4.8 0.27 33 28
11 T21, VSD 0.82 7.5 0.38 34 30
12 VSD 0.09 3.9 0.25 61 25
13 T21, AVSD 0.10 3.7 0.24 78 25
14 T21, AVSD 0.10 6.5 0.32 70 25
15 MVR 0.31 4.8 0.30 79 18
Group 1, ventilation <2 d 0.53 ± 0.62 5.7 ± 1.9 0.31 ± 0.7 49 ± 21 26.8 ± 2.6
Group 2, ventilation >2 d 0.39 ± 0.29 5.4 ± 1.4 0.30 ± 0.05 61 ± 22 24.0 ± 5.0
P value (group 1 vs 2) .52 .71 .73 .39 .16
BSA, Body surface area; XCT, crossclamp time; Temperature, lowest temperature during CPB; Dex, single dose of dexamethasone given during CPB; Dopa, maxi-
mum dopamine (µg · kg–1 · min–1) during postoperative course; T21, trisomy 21; VSD, ventricular septal defect; AoPW, aortopulmonary window; AVSD, atrioven-
tricular septal defect; PDA, patent ductus arteriosus; MVR, mitral valve replacement.
in millimeters of mercury per liter per minute) and PVR
index (ie, PVR times square meter) were derived from the
transpulmonary pressure gradient and reported in Wood units
(WU) indexed to body surface area (WU times square meter).
Protocol for evaluation of PVR. The study protocol was
instituted after a cardiorespiratory steady state was confirmed
during 5 to 10 minutes of monitoring. Measurements of oxy-
gen consumption, cardiac output, and hemodynamic pres-
sures began at baseline during ventilation with low fraction of
inspired oxygen (FIO2; range, 0.21-0.35) and were then made
at the steady state value during the last 2 minutes of each new
condition:
1. Ventilation in increased oxygen (FIO2 of 0.65), which
was continued to the end of the protocol to obviate the possi-
ble confounding effects of alveolar hypoxia
2. Infusion (intravenous) of L-arginine (Fresenius, Bad
Homburg, Germany), 15 mg · kg–1 · min–1, which was con-
tinued to the end of the protocol as the substrate for endoge-
nous nitric oxide (NO) production
3. Infusion (intravenous) of substance P (Clinalfa AG,
Laeufelfingen, Switzerland), 1 pmol · kg–1 · min–1, which was
continued to the end of the protocol to stimulate endothelial
NO production
4. Inhalation of NO (The BOC Group, Windlesham,
Surrey, United Kingdom), 20 parts per million, which was
continued to the end of the protocol to provide direct pul-
monary vascular smooth muscle relaxation
Postoperative mechanical ventilation. Postoperative ven-
tilation was used as an index of postoperative recovery and
was measured as the time in hours between arrival at the
intensive care unit and successful extubation. All medica-
tions, including inhaled NO, were stopped at the end of the
study protocol. In those requiring therapeutic manipulation of
PVR, sedation, and paralysis were continued or reinstituted,
and intermittent positive-pressure ventilation was adjusted to
optimize ventilation. Where necessary (see “Results” sec-
tion), inhaled NO was reinstituted (5-20 ppm) by the clinical
care providers. Subsequent weaning from ventilation with
inhaled NO was performed by gradually reducing inhaled
NO to 1 to 2 ppm before withdrawal, while transiently receiv-
ing increased FIO2 (0.6-1.0). Subsequently, sedation was
reduced, and ventilatory settings were gradually reduced as
appropriate for ventilatory weaning.
Statistical analysis. All data are expressed as means ± SD.
A repeated-measures analysis of variance was used to ana-
lyze serial hemodynamic and metabolic data over time, and a
post hoc paired t test with Bonferroni correction was applied
when appropriate to evaluate for significant differences
between conditions and individual time points.
Results
Patients. Fifteen infants (mean age, 0.53 years;
median age, 0.31 years; mean weight, 5.6 kg; median
weight, 5.1 kg), all but one with intracardiac shunt and
at risk of pulmonary hypertension, were studied (Table
I). They all underwent corrective cardiac operations
involving CPB (range, 49-147 minutes; median, 65
minutes) with a minimum temperature of 18°C to
30°C (median, 25°C). Hemodynamic measurements at
the start of the protocol, including metabolic variables,
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Dex CPB Ventilation Dopamine Maximum PVR Minimum PVR Fall in PVR 
(mg) (min) (d) (µg · kg–1 · min–1) (WU · m2) (WU · m2) (%)
— 147 1.74 4 7.4 6.1 82
— 60 1.12 5 14.4 5.4 38
— 57 2.50 2 15.3 5.3 34
124 50 0.88 3 8.5 3.5 41
121 117 14.99 7 15.8 12.9 84
— 64 0.87 2 5.6 2.7 48
— 60 0.92 5 3.4 1.6 47
125 120 0.99 5 12.4 3.5 28
— 65 0.95 2 8.0 5.7 71
150 56 1.75 3 8.7 4.3 50
— 49 5.50 4 14.1 7.6 54
118 95 1.89 5 13.8 5.6 41
100 112 7.94 7 21.6 13.9 64
192 107 3.96 2 6.1 3.6 59
— 120 14.69 5 21.7 8.9 41
129 ± 14 79 ± 34 1.23 ± 0.43 3.4 ± 1.8 9.1 ± 3.7 4.3 ± 1.6 50 ± 17
142 ± 40 94 ± 32 8.26 ± 5.41 4.5 ± 2.3 15.8 ± 5.8 8.6 ± 4.1 55 ± 17
.59 .43 .002 .33 .017 .012 .52
were in the normal reported range for this situation,5
with the exception of increased pulmonary artery pres-
sures, decreased cardiac output, and increased PVR in
all patients (Table II). The median time from return to
the intensive care unit until successful extubation was
1.75 days (range, 0.86-14.9 days).
Postoperative course. There were 9 patients (group
1) with an intubation time of less than 2 days (median,
0.99 days), leaving 6 patients (group 2) with prolonged
mechanical ventilation (median, 6.7 days). Although
CPB time, dexamethasone dose at CPB, and necessary
inotropic support until extubation in both groups were
not statistically different (Table I), there was a correla-
tion between the length of CPB time and the duration
of ventilatory support time in group 2 patients (r2 =
0.48, P < .01). Three patients (patients 5, 11, and 15)
received NO for pulmonary hypertension crises (ie, an
acute rise in pulmonary artery pressure associated with
desaturation, systemic hypotension, and ventilatory dif-
ficulty caused by still lungs in 2 patients), and the
remainder required prolonged sedation and ventilation
to prevent pulmonary hypertension associated with
wakefulness, tracheal suctioning-physiotherapy, or
weaning. Two patients (patients 5 and 15) had addi-
tional signs of multiorgan failure and capillary leak,
and 2 (patients 5 and 13) had pulmonary atelectasis and
infection. Neither the presence of trisomy 21 nor treat-
ment with steroids during CPB caused a significant dif-
ference in the response of the pulmonary vasculature or
ventilatory time.
Study protocol. During the study protocol, arterial
PCO2 or blood pH did not change. Systemic arterial
pressure fell in response to the systemic infusion of
substance P (Fig 1), but no patient required clinical
intervention. After the application of oxygen, pul-
monary artery pressure fell in group 1 patients and con-
tinued to do so in the subsequent steps of the study pro-
tocol, whereas in patient group 2 a further fall in pul-
monary artery pressure did not occur (Fig 1). The
application of oxygen tended to expose a greater alve-
olar-arterial oxygen gradient in group 2 than in group
1. Although oxygen consumption was not different in
either patient group, cardiac output (baseline, 1.97 ±
1.27 L · min–1 · m–2 [group 2] vs 2.62 ± 1.26 L · min–1
· m–2 [group 1]; increasing during the study protocol to
a maximum of 3.17 ± 2.15 L · min–1 · m–2 [group 2] vs
4.13 ± 2.53 L · min–1 · m–2 [group 1]) and therefore
oxygen delivery (Fig 2) were significantly depressed in
patient group 2 throughout the protocol. Oxygen
extraction (oxygen consumption/delivery ratio) was
greater at all protocol steps compared with that of
patient group 1 (Fig 2).
PVR at baseline was 11.7 ± 5.6 WU · m2, which fell to
9.3 ± 5.2 WU · m2 at an FIO2 of 0.65 and then to its low-
est level of 6.1 ± 3.5 WU · m2 during the further steps of
the protocol. PVR in group 1 was significantly lower at
all stages of the study protocol compared with that of
group 2 (Fig 3), but the absolute and percentage change
in PVR reduction during the study protocol was the
same in both patient groups (4.8 ± 3.1 vs 7.1 ± 4.1 
WU · m1 [body surface area], P = .23; 50% ± 17% vs
45% ± 17%, P = .52). The duration of ventilation did not
correlate with cardiac index at baseline (r2 = 0.1, P =
.56), maximum cardiac index (r2 = 0.09, P = .89), base-
line PVR (r2 = 0.208, P = .43), or the amount of PVR
reduction during the protocol (r2 = 0.121, P = .51) but
did correlate with PVR obtained after the infusion of
substance P (r2 = 0.55, P = .011) and the lowest PVR (r2
= 0.64, P < .01; Fig 4).
Discussion
Pulmonary hypertension in children with congenital
heart disease remains an important cause of postopera-
tive morbidity and mortality. This study shows that the
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Table II. Baseline gas exchange and hemodynamic data
Variable Group 1 (mean ± SD) Group 2 (mean ± SD) P value
Systemic arterial pressure (mm Hg) 60 ± 7 60 ± 6 .92
Pulmonary arterial pressure (mm Hg) 20 ± 5 26 ± 8 .75
Arterial oxygen partial pressure (kPa)
FIO2 = 0.21 9.6 ± 2.1 8.9 ± 2.2 .89
FIO2 = 0.65 32.4 ± 6.3 25.8 ± 10.1 <.01
·VO2 (mL · min–1 · m–2) 135 ± 30 139 ± 47 .68
Cardiac index (L · min–1 · m–2) 2.65 ± 1.27 1.98 ± 1.29 <.05
DO2 (mL · min–1 · m–2) 407 ± 173 292 ± 134 <.01
·VO2/DO2 ratio (%) 37 ± 13 51 ± 12 <.01
PVR index (WU · m2) 9.1 ± 3.7 15.7 ± 5.7 <.01
NS, Not significant; ·VO2, oxygen consumption; DO2, oxygen delivery.
nonreversible element of postoperatively raised PVR,
as measured in the immediate postoperative period, is
directly correlated with the speed of postoperative
recovery. 
In our patients, postoperative baseline PVR was
increased. Increased PVR in children with congenital
heart disease, both preoperatively and postoperatively,
has been ascribed to pulmonary endothelial dysfunc-
tion (ie, a failure of the endothelium to produce ade-
quate amounts of NO in the presence of vascular
smooth muscle cells, which are able to vasodilate on
administration of exogenous sources of NO, such as
nitroprusside or inhaled NO).6,7 Wessel and associates8
showed pulmonary endothelial dysfunction in a group
of children after CPB operations for congenital heart
disease by demonstrating the failure of pulmonary
vasodilation in response to infused acetylcholine.
However, in a previous study this pulmonary endothe-
lial dysfunction was shown to be reversible by using
substance P, a non-G protein–dependent cellular path-
way of endothelial NO production.1 However, regard-
less of the precise underlying mechanism, the current
study showed that it is not pulmonary endothelial dys-
function and the amount of reversibly increased PVR
associated with it that determined postoperative recov-
ery in our patients but rather the residual PVR after
supplementation of the L-arginine/NO pathway.
Increased PVR after CPB has been attributed to fac-
tors other than pulmonary endothelial dysfunction.
Cardiac operations with CPB have direct adverse
mechanical effects on the lung, resulting from deflation
and manipulation during the operations (eg, infection),
but may also be affected secondarily as part of a gener-
alized inflammatory reaction. CPB causes activation of
inflammatory pathways, leukocytes, and platelets,9,10
which results in the production of vasoconstrictive fac-
tors, such as thromboxanes and endothelins.11,12
Furthermore, preoperative pulmonary endothelial dys-
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Fig 1. Hemodynamic and gas-exchange variables during
study protocol. All values are displayed as means ± SEM.
Filled circles, Patients receiving ventilatory support for less
than 2 postoperative days; open circles, patients receiving
ventilatory support for more than 2 postoperative days; base,
baseline; O2, inspired FIO2 of 0.65; L-Arg, infusion of L-
arginine (15 mg · kg–1 · min–1); Sub P, infusion of substance
P (1 pmol · kg–1 · min–1); inh NO, inhaled NO (20 ppm).
Statistical significance of differences between patient groups
is indicated as P values; values are not significant where not
indicated.
Fig 2. Oxygen consumption, oxygen delivery, and the ratio
during study protocol. NS, Not significant. Other symbols
and abbreviations are as shown in legend of Fig 1.
function may amplify this injury to the pulmonary vas-
cular bed. One study13 showed that the level of circu-
lating endothelin, as well as the increase in PVR after
CPB, corresponded to the amount of preoperatively
increased pulmonary blood flow, and another study
showed that removal of postoperative endothelin by
means of ultrafiltration resulted in a lower postopera-
tive PVR.14 It remains true that patients with congeni-
tal heart disease being operated on according to con-
temporary surgical algorithms continue to sustain
pulmonary damage both directly and as part of the
whole-body inflammatory response to contact activa-
tion, hypothermia, hemodilution, and ischemia during
CPB. Although treatment strategies designed to reduce
the specific pulmonary disease (eg, endothelin block-
ade and improved ventilatory management) may be
beneficial, therapies directed toward suppression of the
generalized systemic inflammatory response syndrome
after CPB15 may be equally effective.
There were no clinical or echocardiographic indica-
tions of significant preoperative pulmonary vascular
disease justifying catheterization, and therefore there
were no preoperative PVR data to correlate with our
postoperative findings. Furthermore, we were unable to
correlate clinical improvement directly with changes or
improvement of PVR. Nonetheless, our data remain a
valid reflection of the relationship between early post-
operative findings and subsequent outcomes.
Summary
We measured PVR in infants with intracardiac left-
to-right shunting defects early after CPB, differentiat-
ing those components of pulmonary endothelial dys-
function that were restorable in the short term and
those that were not. Increased PVR after maximal treat-
ment of the L-arginine/NO pathway was significantly
related to the need for postoperative mechanical venti-
latory support. Additional strategies directed toward
this nonreversible component of postoperative pul-
monary vascular dysfunction may have significant clin-
ical effect.
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